Telepharmacy Cuts Blood Pressure and Boosts Medication Adherence in Chronic Disease Patients
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
Summary
A Cochrane systematic review analyzed 21 randomized controlled trials involving 5,440 patients with non-communicable diseases such as hypertension, diabetes, and asthma. Telepharmacy — pharmacist-led care delivered by phone, video, or app — was compared to usual care. Results showed low-certainty evidence that telepharmacy may modestly improve medication adherence and reduce systolic blood pressure by nearly 7 mmHg. Moderate-certainty evidence found little to no effect on HbA1c in diabetic patients. Patient satisfaction data were inconclusive, and outcomes like mortality and quality of life showed no consistent benefit. The authors conclude telepharmacy is promising but call for larger, longer trials with standardized outcome measures before widespread adoption.
Detailed Summary
Medication non-adherence is one of the most persistent challenges in managing chronic diseases like hypertension, diabetes, and asthma — conditions that collectively drive a significant share of global mortality and disability. Remote pharmacist services delivered via telephone, video, or digital apps offer a scalable way to close this gap, but their clinical effectiveness had not been rigorously synthesized until now.
This Cochrane systematic review included 21 randomized controlled trials (17 individual RCTs and 4 cluster-RCTs) encompassing 5,440 participants across high-, upper-middle-, and lower-middle-income countries. Interventions varied in delivery mode and intensity but consistently involved pharmacist-led medication management, adherence support, and patient education provided remotely.
The headline findings are meaningful but qualified. Telepharmacy may improve medication adherence (SMD 0.32, 95% CI 0.10 to 0.55; low-certainty evidence) and appears to reduce systolic blood pressure by approximately 6.8 mmHg (95% CI -12.16 to -1.48) and diastolic blood pressure by 2.5 mmHg (95% CI -4.80 to -0.20) — clinically significant reductions at the population level, though based on low-certainty evidence. HbA1c showed little to no change (MD -0.10%; moderate-certainty evidence), and patient satisfaction data were very uncertain.
For clinicians managing hypertensive patients remotely, these blood pressure findings are particularly actionable. A near-7 mmHg reduction in systolic pressure is comparable to the effect of adding a low-dose antihypertensive agent and could translate into meaningful cardiovascular risk reduction over time. For diabetes management, the null HbA1c finding tempers enthusiasm and suggests telepharmacy alone is insufficient to drive glycemic control.
Important caveats apply. Most studies lasted 12 months or less, limiting conclusions about long-term sustainability. Intervention designs varied widely, making it difficult to identify which specific components drive benefit. No included studies reported mortality data or adverse events attributable to telepharmacy, so potential harms remain uncertain, and equity-related outcomes were largely absent.
Key Findings
- Telepharmacy may improve medication adherence across NCD conditions (SMD 0.32; low-certainty evidence).
- Systolic blood pressure reduced by ~6.8 mmHg with telepharmacy vs. usual care across 5 studies.
- Diastolic blood pressure reduced by ~2.5 mmHg, a clinically meaningful secondary finding.
- HbA1c showed little to no improvement with telepharmacy (moderate-certainty evidence).
- No mortality data were reported; long-term safety and equity impacts remain unknown.
Methodology
This Cochrane review included 21 RCTs (17 individual, 4 cluster) with 5,440 participants across multiple countries and NCD conditions. Meta-analyses used random-effects models with GRADE certainty ratings; cluster-RCTs were adjusted for design effects. Where heterogeneity precluded pooling, narrative synthesis was applied.
Study Limitations
Evidence certainty was rated low to very low for most outcomes (except HbA1c, which was moderate-certainty), limiting confidence in conclusions. Follow-up durations were predominantly 12 months or less, preventing assessment of long-term effects. No studies reported mortality or harms attributable to telepharmacy, and equity-related data were largely absent. Intervention heterogeneity across delivery modes and intensities limits identification of the most effective components.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.